Written by: Jeff Engle, PharmD, MS
This PQI will discuss effective management of adverse effects of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.
Continue reading Sorafenib (Nexavar) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)
Written by: Bryan J. Brinda, PharmD
This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication.
Continue reading Gilteritinib (Xospata®) for Relapsed/Refractory Acute Myeloid Leukemia